Présentation
Tiziana BONALDI
Department of Experimental Oncology, European Institute of Oncology (IEO), Milano -Italy)
External attendees wishing to participate in the seminar are required to contact the following email address dbsc@pasteur.fr in order to obtain access to the Institut Pasteur premises at least one week before the event.
Abstract
Resistance to cancer therapy is often driven by adaptive epigenetic and proteomic rewiring rather than fixed genetic alterations. In this seminar, I will present how epi-proteomics approaches can be used to systematically dissect changes in chromatin states and protein methylation programs that sustain tumor cell survival under therapeutic pressure.
Using mass spectrometry–based profiling of histone and non-histone methylation of clinical and pre-clinical samples, combined with functional perturbation, we have characterized cancer-specific methylation landscapes in triple-negative breast cancer (TNBC)and high-grade ovarian cancer. In TNBC, analysis of patient-derived material revealed sustained H3K4me3-associated transcriptional programs supporting aggressive tumor phenotypes. In ovarian cancer, ongoing work identifies alterations in H3K27me3 linked to platinum resistance, highlighting epigenetic plasticity as a key determinant of chemoresistant states
Finally, I will briefly introduce methyl-proteomics strategies to explore non-histone methylation as an additional regulatory layer in cancer therapy resistance.



